Qin Wei, Li Yi-Heng, Tong Jing, Wu Jie, Zhao Dong, Li Hui-Jin, Xing Lu, He Chun-Xia, Zhou Xin, Li Peng-Quan, Meng Ge, Wu Shao-Ping, Cao Hui-Ling
Xi'an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
College of Life Sciences, Northwest University, Xi'an, China.
Front Mol Biosci. 2022 Jan 24;8:805594. doi: 10.3389/fmolb.2021.805594. eCollection 2021.
Atrial fibrillation (AF) is the most common clinical sustained arrhythmia; clinical therapeutic drugs have low atrial selectivity and might cause more severe ventricle arrhythmias while stopping AF. As an anti-AF drug target with high selectivity on the atrial muscle cells, the undetermined crystal structure of Kv1.5 potassium channel impeded further new drug development. Herein, with the simulated 3D structure of Kv1.5 as the drug target, a series of 3-morpholine linked aromatic amino substituted 1-indoles as novel Kv1.5 channel inhibitors were designed and synthesized based on target-ligand interaction analysis. The synthesis route was practical, starting from commercially available material, and the chemical structures of target compounds were characterized. It was indicated that compounds and (100 μM) exhibited favorable inhibitory activity against the Kv1.5 channel with an inhibition rate of 70.8 and 57.5% using a patch clamp technique. All compounds did not exhibit off-target effects against other drug targets, which denoted some selectivity on the Kv1.5 channel. Interestingly, twelve compounds exhibited favorable vasodilation activity on pre-contracted arterial rings using KCl or phenylephrine (PE) by a Myograph. The vasodilation rates of compounds and (100 μM) even reached over 90%, which would provide potential lead compounds for both anti-AF and anti-hypertension new drug development.
心房颤动(AF)是最常见的临床持续性心律失常;临床治疗药物的心房选择性较低,在终止房颤时可能会引发更严重的室性心律失常。作为一种对心房肌细胞具有高选择性的抗房颤药物靶点,Kv1.5钾通道尚未确定的晶体结构阻碍了进一步的新药研发。在此,以Kv1.5的模拟三维结构作为药物靶点,基于靶点-配体相互作用分析,设计并合成了一系列以3-吗啉连接的芳香氨基取代的1-吲哚作为新型Kv1.5通道抑制剂。合成路线切实可行,从市售原料出发,对目标化合物的化学结构进行了表征。结果表明,化合物 和 (100 μM)对Kv1.5通道表现出良好的抑制活性,采用膜片钳技术测得的抑制率分别为70.8%和57.5%。所有化合物对其他药物靶点均未表现出脱靶效应,这表明对Kv1.5通道具有一定的选择性。有趣的是,有12种化合物通过肌张力测定仪对氯化钾或去氧肾上腺素(PE)预收缩的动脉环表现出良好的血管舒张活性。化合物 和 (100 μM)的血管舒张率甚至超过90%,这将为抗房颤和抗高血压新药研发提供潜在的先导化合物。